<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01235819</url>
  </required_header>
  <id_info>
    <org_study_id>DM/CHCC/03/2010</org_study_id>
    <nct_id>NCT01235819</nct_id>
  </id_info>
  <brief_title>Comparison Between GLP 1 Analogues and DPP 4 Inhibitors in Type 1 Diabetes Mellitus</brief_title>
  <official_title>Comparison Between GLP 1 Analogues and DPP 4 Inhibitors in Type 1 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Command Hospital, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Command Hospital, India</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the effects of GLP 1 analogues and DPP 4 inhibitors on newly detected type 1
      diabetes patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inclusion criteria T1DM &lt;3 months GAD Antibody+ Stimulated C peptide&lt;0.5ng/ml Ketosis at
      onset Age &lt; 30 yr Exclusion criteria Age &gt; 30 yr Pancreatic disease significant systemic
      complication
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in insulin requirement</measure>
    <time_frame>one year</time_frame>
    <description>To assess the change in insulin requirement with use of GLP 1 analogues or DPP 4 inhibitors along with insulin in type 1 diabetes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>C peptide response</measure>
    <time_frame>at the end of one year</time_frame>
    <description>To assess the endogenous insulin secretion after one year of use of GLp 1 analogue and DPP 4 inhibitors</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Insulin alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Type 1 DM only on Insulin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin and Exenatide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Newly detected Type 1 DM on Insulin and exenatide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin and Sitagliptin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Newly detected Type 1 DM using Insulin and Sitagliptin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <description>Exenatide Sitagliptin</description>
    <arm_group_label>Insulin alone</arm_group_label>
    <other_name>Premixed Insulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>Sitagliptin 100 mg per day oral</description>
    <arm_group_label>Insulin and Sitagliptin</arm_group_label>
    <other_name>DPP 4 inhibitors</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exenatide</intervention_name>
    <description>Exenatide 10 micrograms daily twice</description>
    <arm_group_label>Insulin and Exenatide</arm_group_label>
    <other_name>GLP 1 analogues</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  T1DM &lt;3 months

          -  GAD Antibody+ or Stimulated C peptide&lt;0.5 ng/ml

          -  Ketosis at onset

          -  Age &lt; 30 yr

        Exclusion Criteria:

          -  Age &gt; 30 yr

          -  Pancreas disease

          -  Significant systemic disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>The Commandant, MD</last_name>
    <role>Study Director</role>
    <affiliation>Command Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Command Hospital</name>
      <address>
        <city>Lucknow</city>
        <state>UP</state>
        <zip>226002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2010</study_first_submitted>
  <study_first_submitted_qc>November 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2010</study_first_posted>
  <last_update_submitted>July 26, 2016</last_update_submitted>
  <last_update_submitted_qc>July 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Command Hospital, India</investigator_affiliation>
    <investigator_full_name>KVS Hari Kumar</investigator_full_name>
    <investigator_title>Endocrinologist</investigator_title>
  </responsible_party>
  <keyword>type 1 diabetes</keyword>
  <keyword>exenatide</keyword>
  <keyword>sitagliptin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Exenatide</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
    <mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Not permitted</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

